# reload+after+2024-01-23 03:45:29.348915
address1§2855 Gazelle Court
city§Carlsbad
state§CA
zip§92010
country§United States
phone§760 931 9200
website§https://www.ionispharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.
fullTimeEmployees§796
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Brett P. Monia Ph.D.', 'age': 62, 'title': 'Founder, CEO & Director', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 1712958, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Elizabeth L. Hougen M.A., M.B.A., M.S.', 'age': 61, 'title': 'Executive VP of Finance & CFO', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 1015341, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Onaiza  Cadoret-Manier M.A., M.B.A., M.S.', 'age': 58, 'title': 'Executive VP, Chief Global Product Strategy & Operations Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 930820, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. B. Lynne Parshall Esq., J.D.', 'age': 69, 'title': 'Senior Strategic Advisor & Director', 'yearBorn': 1954, 'fiscalYear': 2022, 'totalPay': 334641, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Richard S. Geary Ph.D.', 'age': 65, 'title': 'Executive VP & Chief Development Officer', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 946259, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Joseph T. Baroldi M.A., M.B.A., M.S.', 'age': 44, 'title': 'Executive VP & Chief Business Officer', 'yearBorn': 1979, 'fiscalYear': 2022, 'totalPay': 815865, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Darren  Gonzales', 'title': 'Chief Accounting Officer & Senior VP', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. C. Frank Bennett BSc, Ph.D.', 'age': 66, 'title': 'Executive VP & Chief Scientific Officer', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 651639, 'exercisedValue': 1367979, 'unexercisedValue': 2986721}, {'maxAge': 1, 'name': 'Mr. D. Wade Walke Ph.D.', 'title': 'Senior Vice President of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': "Mr. Patrick R. O'Neil Esq.", 'age': 49, 'title': 'Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 815692, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§2
boardRisk§3
compensationRisk§4
shareHolderRightsRisk§5
overallRisk§3
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.471
priceToSalesTrailing12Months§11.827096
currency§USD
dateShortInterest§1702598400
forwardEps§-3.7
pegRatio§0.29
exchange§NMS
quoteType§EQUITY
shortName§Ionis Pharmaceuticals, Inc.
longName§Ionis Pharmaceuticals, Inc.
firstTradeDateEpochUtc§674487000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§e2f8b663-1b31-3cee-8363-06c9dcf00fd4
gmtOffSetMilliseconds§-18000000
targetHighPrice§85.0
targetLowPrice§28.0
targetMeanPrice§54.62
targetMedianPrice§60.0
recommendationMean§2.4
recommendationKey§buy
numberOfAnalystOpinions§21
quickRatio§5.899
grossMargins§-0.55938
ebitdaMargins§-0.8785
trailingPegRatio§None
